TFF Pharmaceuticals (TFFP) News Today $0.06 0.00 (0.00%) (As of 12/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.70%November 15, 2024 | msn.comTFF Pharmaceuticals Shares Fall 66%; Company to Wind DownNovember 15, 2024 | marketwatch.comTFF Pharmaceuticals terminates employees, to wind down operationsNovember 15, 2024 | markets.businessinsider.comTFF Pharmaceuticals to Dissolve and Liquidate AssetsNovember 15, 2024 | markets.businessinsider.comTFF Pharmaceuticals Announces It Will Wind Down OperationsNovember 14, 2024 | globenewswire.comTFF Pharmaceuticals (NASDAQ:TFFP) Stock Quotes, Forecast and News SummaryOctober 9, 2024 | benzinga.comTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals' Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug DeliverySeptember 26, 2024 | finanznachrichten.deTFF Pharmaceuticals’ Technology Generates Superior Inhalational Dry Powder Formulations for Pulmonary Drug DeliverySeptember 26, 2024 | markets.businessinsider.comTFF Pharmaceuticals Partners with Emory University and BARDA to Develop a Dry Powder Inhaled mRNA-based Treatment for Influenza and COVIDSeptember 11, 2024 | globenewswire.comTFF Pharmaceuticals Announces Positive Preclinical Data from Bivalent Universal Influenza Vaccine Candidates Manufactured by TFF Following Intranasal ImmunizationSeptember 10, 2024 | globenewswire.comTFF Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 4, 2024 | markets.businessinsider.comThe Future of Medicine: Drug Delivery Innovations Leading a $700 Billion MarketAugust 23, 2024 | baystreet.caTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024August 14, 2024 | markets.businessinsider.comTFF Pharmaceuticals Provides Continued Positive Outcomes from Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant RejectionAugust 6, 2024 | globenewswire.comTFF Pharmaceuticals Engages Outcome Capital As a Strategic Advisor for Evaluating Partnership and Licensing OpportunitiesJune 26, 2024 | globenewswire.com3 52-Week-Low Losers Ready to Become Big-Time Stock WinnersJune 19, 2024 | investorplace.comTFF Pharmaceuticals and Leidos to Advance Next-Generation Biodefense Countermeasures Under the DARPA PPB Program into Preclinical TestingMay 23, 2024 | globenewswire.comTFF Pharmaceuticals and Cleveland Clinic to Advance Multivalent Universal Influenza Vaccine Candidates into Preclinical TestingMay 20, 2024 | globenewswire.comBuy Rating Affirmed for TFF Pharmaceuticals Amid Strong Clinical Data and Market PotentialMay 16, 2024 | markets.businessinsider.comTFF Pharmaceuticals Provides Update on Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial for the Prevention of Lung Transplant RejectionMay 15, 2024 | globenewswire.comTFFP Stock Earnings: TFF Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024May 15, 2024 | investorplace.comTFF Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate UpdateMay 14, 2024 | globenewswire.comTFF Pharmaceuticals Announces Closing of Pricing of $4.8 Million Public OfferingMay 1, 2024 | globenewswire.comTFF Pharmaceuticals Announces Pricing of $4.8 Million Public OfferingApril 29, 2024 | globenewswire.comTurkish federation investigates match-fixing allegations in third-tier gameApril 29, 2024 | reuters.comTFF Pharmaceuticals Makes Available Phase 2 Data from Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection Presented at the Recent ISHLT Annual MeetingApril 29, 2024 | globenewswire.comTFF Pharmaceuticals (TFFP) Price Target Decreased by 28.99% to 24.99April 17, 2024 | msn.comTFF Pharmaceuticals Reports Addl. Positive Phase 2 Data For Tacrolimus Inhalation PowderApril 15, 2024 | markets.businessinsider.comTFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase 2 Trial Following Oral Presentation at the ISHLT 44th Annual Late Breaking Clinical Science Abstract SessionsApril 15, 2024 | globenewswire.comTFF Pharmaceuticals Full Year 2023 Earnings: Misses ExpectationsApril 1, 2024 | finance.yahoo.comTFF Pharmaceuticals reports positive phase 2 trial resultsMarch 29, 2024 | investing.comTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 29, 2024 | finanznachrichten.deTFFP Stock Earnings: TFF Pharmaceuticals Beats EPS, Beats Revenue for Q4 2023March 28, 2024 | investorplace.comTFF Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 28, 2024 | globenewswire.comTFF Pharmaceuticals Announces Updated Data from the Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI) Clinical ProgramsMarch 27, 2024 | globenewswire.comTFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of Tacrolimus Inhalation Powder (TFF TAC) for the Prevention of Lung Transplant Rejection at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 MeetingMarch 25, 2024 | globenewswire.comTFF Pharmaceuticals Announces Closing of $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMarch 22, 2024 | globenewswire.comTFF Pharmaceuticals, Inc. (TFFP)March 21, 2024 | finance.yahoo.comTrading was temporarily halted for "TFFP" at 12:03 PM with a stated reason of "LULD pause."March 20, 2024 | marketbeat.comTFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesMarch 20, 2024 | globenewswire.comTFF Pharmaceuticals Announces Update on Clinical ProgramsMarch 20, 2024 | globenewswire.comTFF Pharmaceuticals to Participate in the 36th Annual Roth Conference – March 17-19, 2024March 14, 2024 | globenewswire.comTff Pharmaceuticals Inc (TFFP)March 12, 2024 | uk.investing.comTrading was temporarily halted for "TFFP" at 09:02 AM with a stated reason of "LULD pause."February 29, 2024 | marketbeat.comTFF Pharmaceuticals to Present Data from Phase 2 Trial of Voriconazole Inhalation Powder (TFF VORI) for the Treatment of Invasive Pulmonary Aspergillosis at the 11th Advances Against Aspergillosis & Mucormycosis ConferenceJanuary 24, 2024 | finance.yahoo.comTFF Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for Presentation at the 44th Annual International Society for Heart and Lung Transplantation (ISHLT) 2024 MeetingJanuary 9, 2024 | finance.yahoo.comTFF Pharmaceuticals Inc Ordinary SharesJanuary 5, 2024 | morningstar.comPositive Phase II Results Bolster Buy Rating for TFF Pharmaceuticals with Raised Price TargetDecember 21, 2023 | markets.businessinsider.comTFF Pharmaceuticals, Inc.: TFF Pharmaceuticals Announces Positive Initial Data from Ongoing Phase 2 Trials of TFF VORI and TFF TACDecember 19, 2023 | finanznachrichten.deTFF Pharma Reveals Positive Initial Data From Ongoing Phase 2 Trials Of TFF VORI And TFF TACDecember 19, 2023 | markets.businessinsider.com Get TFF Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TFFP and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Humiliated: Demo of Elon’s Tech Proves They’re Wrong (Ad)Elon Musk believes his new AI product will be worth an incredible $9 trillion. But the mainstream media is not buying it. Click here to watch this demo and decide for yourself. TFFP Media Mentions By Week TFFP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TFFP News Sentiment▼0.000.60▲Average Medical News Sentiment TFFP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TFFP Articles This Week▼01▲TFFP Articles Average Week Get TFF Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TFFP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Ayala Pharmaceuticals News Today Evofem Biosciences News Today PaxMedica News Today Peak Bio News Today Biodexa Pharmaceuticals News Today NexImmune News Today PainReform News Today TC Biopharm News Today Seelos Therapeutics News Today TRACON Pharmaceuticals News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TFFP) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TFF Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TFF Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
